Puma Biotechnology
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 185
- Market Cap
- $124.5M
- Introduction
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
Evaluating how well and how safely Alisertib works with hormone therapy in treating patients with breast cancer that has come back or spread (hormone receptor positive, HER2 negative
- Conditions
- Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer (MBC)
- Interventions
- Drug: Endocrine therapy
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Puma Biotechnology Inc.
- Target Recruit Count
- 54
- Registration Number
- 2024-511497-79-00
- Locations
- 🇺🇸
Alabama Oncology, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸City of Hope at Orange County Lennar Foundation Cancer Center, Irvine, California, United States
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06095505
- Locations
- 🇺🇸
Southern Cancer Center, Daphne, Alabama, United States
🇺🇸The Oncology Institute of Hope and Innovation, Fort Lauderdale, Florida, United States
🇺🇸Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States
A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib
- Conditions
- HER2 Amplified Breast Cancer
- Interventions
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04366713
- Locations
- 🇵🇹
Hospital CUF Descobertas, Lisboa, Portugal
HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib
- Conditions
- Metastatic Cervical CancerHormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 1583
- Registration Number
- NCT03786107
- Locations
- 🇺🇸
Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
🇫🇷Institut Curie, Saint-Cloud, France
🇮🇪Cork University Hospital, Wilton, Cork, Ireland
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
- Conditions
- Early Stage HER2+ Breast Cancer
- Interventions
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 563
- Registration Number
- NCT02400476
- Locations
- 🇺🇸
Alabama Oncology, Birmingham, Alabama, United States
🇺🇸Compassionate Care Research Group Inc., Riverside, California, United States
🇺🇸St. Joseph Heritage Healthcare, Fullerton, California, United States
Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects
- First Posted Date
- 2015-01-08
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02334501
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
- Conditions
- Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
- Interventions
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 582
- Registration Number
- NCT01953926
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer
- Conditions
- HER2-mutant Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT01827267
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of California Los Angeles, Santa Monica, California, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
- Conditions
- HER2+ Metastatic Breast Cancer (MBC)
- Interventions
- First Posted Date
- 2013-03-11
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 621
- Registration Number
- NCT01808573
- Locations
- 🇺🇸
Ironwood Cancer and Research Centers, Scottsdale, Arizona, United States
🇺🇸UCLA Hematology Oncology, Santa Monica, California, United States
🇺🇸CBCC Global Research, Inc. at Comprehensive Blood and Caner Center, Bakersfield, California, United States
A Single Dose Bioequivalence Study Of Neratinib In Healthy Subjects
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT01142063
- Locations
- 🇺🇸
Investigational Site, New Haven, Connecticut, United States